Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

RecoveryRx® Accelerated healing and better pain relief

618 views

Published on

See why Doctors are switching their patients to RecoveryRx® for reliable, drug-free pain relief and faster healing with no side-effects. Safer, and more effective, see why RecoveryRx is the #1 most innovative pain and healing product and is now available in the US.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

RecoveryRx® Accelerated healing and better pain relief

  1. 1. OUR MISSION: OUR MISSION AT ECHELON IS TO HELP PEOPLE ACHIEVE THEIR HIGHEST POTENTIAL TO LIVE HAPPY, PRODUCTIVE LIVES THROUGH OPTIMAL HEALTH AND WELLNESS. 2
  2. 2. Bioelectroceutical™ Therapy Advances in Healing and Pain Managementwww.EchelonHealthPro.com 3
  3. 3. Device Specifications: Carrier frequency 27.12MHz Peak power 72 milliWatts/cm2 Pulse rate 1 KHz Pulse duration 100 microsecond Power source Battery Antenna size 12cm or 8cm Treatment area 100cm2 of 70cm2 Weight 8 grams Therapy Duration 24-hours a day Battery Life 720 hours on/off capability 27 www.EchelonHealthPro.com
  4. 4. Innovative Pulsed Bioelectric Therapy • Reduces pain and inflammation and accelerates healing • Increases wound tensile strength • Reduces chance of infection, dehiscence and scarring • No adverse side effects • Easy to use over bandages and wound dressings • Inexpensive and labor free • Significant reduced need for pain medications • Clinically Proven Technology • Seven published refereed medical journal studies. • Confirming medical research at Tufts Medical and Dental School; University of Chicago Medical School; University of British Columbia; University Hospital Ghent, Belgium; University Hospital G. Martin, Messina, Italy and University of Otago, Dunedin, New Zealand. 4 www.EchelonHealthPro.com
  5. 5. Mechanism of Action Accelerated Healing Increased blood flow serves to warm the injured region and bring oxygen and nutrients to the region to enhance tissue healing. The extended duration treatment of pulsed EMF has also been shown to directly enhance cell mobility, which accelerates tissue healing. Safe and Effective Pain Relief The physiological response effects of pulsed electromagnetic fields are achieved with the soft tissue through a mechanism referred to as stochastic resonance. Stochastic resonance is a phenomenon where a periodic signal is boosted over a critical threshold by ambient noise in the system. The EMF of 27 MHz penetrates deeply into the body tissues, creating low level electrical fields which, in combination with electrical "noise" in the tissues, is able to significantly influence nerve activity. Activated sensory nerves operate through a feedback loop to trigger motor nerves which results in muscle contractions. The increased muscle activity enhances blood flow into the treated area, and as well, pumps out lymphatic fluid to reduce swelling and pain. 6 www.EchelonHealthPro.com
  6. 6. Clinical Effects of RecoveryRx® When an injury occurs, cells separate and swelling starts to develop in the injured tissues which causes pain. Also, chemical signals are released by cells in the injury site activating nerves and causing an electrical impulse which signals pain in the injured tissue. Therefore, a reduction in tissue swelling “inflammation” reduces pain and allows injuries to heal. Injured Tissue RecoveryRx® accelerates injury recovery by increasing blood flow and reducing swelling. RecoveryRx® delivers a safe form of energy to the injured cells, which is used by the cells to recover and reduce inflammation. The application of this extended treatment device therefore results in a decrease in pain and accelerated tissue repair. Inflammation and swelling cause pain Healing Tissue The inflammation and swelling is reduced resulting in pain relief 29 www.EchelonHealthPro.com
  7. 7. Biological Evidence of Effectiveness • Research has shown up-regulation of both mRNA and opioid peptide in response to exposure to pulsed shortwave electromagnetic field at 27.12MHZ1. • Cellular, animal and clinical results provide support for Ca/CaM-dependent NO production as an important mediator that may explain the observed effects of pulsed shortwave on tissue repair, angiogenesis, pain and inflammation in many studies2. • Cellular and clinical research has shown pulsed shortwave therapy decreases inflammation3. • Studied effects on diabetic mice show decreased time to heal wounds and increased collagen production4. Overall Mechanism 1. Moffett J, Fray LM, Kubat NJ: Activation of endogenous opioid gene expression in human keratinocytes and fibroblasts by pulsed radiofrequency energy fields. J Pain Res 5, 347-357 (2012). 2. Pilla AA: Nonthermal electromagnetic fields: From first messenger to therapeutic applications. Electromagn Biol Med 32(2), 123-136 (2013). 3. Rohde C, Chiang A, Adipoju O, Casper D, Pilla AA: Effects of pulsed electromagnetic fields on interleukin-1 beta and postoperative pain: a double- blind, placebo-controlled, pilot study in breast reduction patients. Plast Reconstr Surg 125(6), 1620-1629 (2010). 4. Kao HK, Li Q, Flynn B et al.: Collagen synthesis modulated in wounds treated by pulsed radiofrequency energy. Plast Reconstr Surg 131(4), 490e- 498e (2013). 30 www.EchelonHealthPro.com
  8. 8. In Vitro Wound Healing Experiment: • Human dermal fibroblasts grown to confluence in cell culture dishes treated with mitomycin C to inhibit proliferation and re-plated to form uniform monolayers. • Cell monolayers were then wounded and exposed to RecoveryRxor untreated controls. • Wound area assessed on day 1, day 2 and day 3 and expressed as wound size and percent of wound closure – (wound size assessed by three blinded researchers). • On each day the treated cells wound size was significantly smaller. At day 3 wound closure was 75% in the treated cell compared to 50% in the untreated cells. Cell culture demonstrate of cell migration, a critical aspect of wound healing C = Control untreated E = Experimental treated 7 www.EchelonHealthPro.com
  9. 9. Human Skin Wounds Experiment • Experiment 1: Full thickness 2 cm wounds inner calf of a volunteer – placebo or actively treated – biopsied at 9 months • Experiment 2: double blind randomized experiment - 20 volunteers 3 mm diameter full thickness wounds – 10 placebo – 10 actively treated. Biopsy at 1, 2, 3, 5, 7 and 14 days. Results Active RF treatment provides earlier: • Epidermal budding • Migration into the wound • Appearance of rete ridges • Normal depth of final epidermis Conclusion • Rate of healing was accelerated and the healed epidermis was more like normal skin than the scar tissue. • Active treated wounds healed in 39 days vs. placebo 54 days (Experiment #1) R.H.C. Bentall, LOW-LEVEL PULSED RADIOFREQUENCY FIELDS AND THE TREATMENT OF SOFT-TISSUE INJURIES. (1986) Bioelectrochemistry and Bioenergetics, 16 (1986) 531-548 8 www.EchelonHealthPro.com
  10. 10. Wound Healing Case Studies 9 www.EchelonHealthPro.com
  11. 11. Case Series: Published in the International Wound Journal • 4 patients: 3 with diabetic ulcers, 1 venous stasis ulcer. • Present longer than 4 months. • Wagner Grade II or higher. • Failed to heal after a variety of other treatments. The use of a portable, wearable form of pulsed radio frequency electromagnetic energy device for the healing of recalcitrant ulcers: a case report. Rawe IM, Vlahovic TC. Int Wound J. 2012 Jun;9(3):253-8. doi: 10.1111/j.1742-481X.2011.00853.x. Epub 2011 Sep 20. 10 www.EchelonHealthPro.com
  12. 12. Case Series: Venous Stasis Ulcer The venous stasis ulcer of patient 1 is shown at week 0 , week 2, week, 4 and week 6 of RecoveryRx® treatment. Significant pain relief was reported by the patient after 2 weeks treatment. The ulcer had decreased in size from 4.0 x 2.5 cm to 0.7 x 0.5 cm after 6 weeks RecoveryRx® treatment. The ulcer continued onto healing using the PRFE therapy. 11 www.EchelonHealthPro.com
  13. 13. Case Series: Diabetic foot Ulcer Patient 2 had a 0.5 x 0.5 cm diabetic ulcer at the beginning of RecoveryRx® treatment, which healed after 3 weeks RecoveryRx® therapy. The ulcer at week 0, week 1 and week 3 is shown. 12 www.EchelonHealthPro.com
  14. 14. Case Series: Wound Measurements Patient Age Location Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 1 66 right leg 4 x 2.5 4 x 2.3 4 x 2 3 x 1.5 2 x 1.5 1 x 0.7 0.7 x 0.5 2 60 right foot 0.5 x 0.5 0.3 x0.3 0.2 x 0.1 ulcer healed 3 43 left heel 4 x 1 2 x 0.5 1 x 0.3 ulcer healed 4 74 right heel 2.5 x 1.75 2 X 2 2 X 1.5 1.7 X 0.7 1 X 1 1 X 0.5 1 X 0.5 • Ulcers had failed to heal with prior therapies. • Only change in treatment was addition of RecoveryRx®. • Ulcers showed a rapid response to RecoveryRx® treatment. • Case 1 and Case 4 went onto to complete healing with continued RecoveryRx® use. 13 www.EchelonHealthPro.com
  15. 15. Exposed Prosthetic Vein Case Study Left leg ulcer with exposed vascular prosthetic vein. Treatment consisted of debridement and two weeks of negative pressure wound therapy and then RecoveryRx® was introduced with polymeric dressing. The ulcer was 50% reduced in three weeks and went onto complete closure. VAS pain 7 VAS pain 2 14 www.EchelonHealthPro.com
  16. 16. RecoveryRx® Resolution of Inflammation – Clinical Evidence Pyoderma gangrenosum: skin ulcer linked to systemic inflammatory illness. Standard therapy - Underlying chronic wound inflammation treated with systemic drug therapy consisting of immunosuppressant's and corticosteroids. RecoveryRx® was introduced, left panel is before treatment, middle panel 2 weeks therapy, pain had been eliminated and ulcers moved rapidly into healing phase. Right panel, ulcers healed in 11 weeks. Patient with two pyoderma ulcers present for 2 years, vicodin used as a pain medication. 15 www.EchelonHealthPro.com
  17. 17. Venous Stasis Ulcer Patient RecoveryRx® DeviceUlcer present 1 year. Amputation was being considered before RecoveryRx® treatment. The wound closed after 6 weeks RecoveryRx® therapy. 18 www.EchelonHealthPro.com
  18. 18. Split Skin Graft The split skin graft was successful, pain controlled and the remaining open wound healed with the combination of pulsed radiofrequency electromagnetic field and polymeric silver dressing Pain VAS 7 Pain VAS 0 19 www.EchelonHealthPro.com
  19. 19. Persistent Chronic Wound Pain Case Studies 20 www.EchelonHealthPro.com
  20. 20. Pyoderma Gangrenosum Pyoderma ulcer on the foot for 2 years and failed systemic corticosteroid and immunosuppressant therapy. The wound base 50% red and 50% yellow with moderate serous exudate VAS pain 4. RecoveryRx® - pain declined to 0 > 1 year, change wound bed from the 50% red, 50% yellow to a 100% red granular wound bed (figure 2) and a decrease in serous exudate from moderate to low. 21 www.EchelonHealthPro.com
  21. 21. • Pyoderma ulcer present 3 yrs. Persistent and significant wound pain VAS 4 and wound drainage moderate • Ulcer treated constantly with RecoveryRx® for 5 months, pain controlled VAS 0/1, wound drainage low, slowly healing • 8 months RecoveryRx® therapy healed greater than 50%, pain controlled, low wound drainage. • 9 months continuing to heal, pain controlled VAS 0 22 www.EchelonHealthPro.com
  22. 22. 66 year old male with 15yr history of scleroderma. Leg ulceration worsening over past 5 years. 12 x Percocet daily (Hydrocodone/paracetamol) short acting (fentanyl) narcotics. 8 x Percocet daily (Hydrocodone/paracetamol) short acting (fentanyl) narcotics eliminated. After 4 months withdrawal challenged - pain returned after discontinuing ActiPatch and markedly reduced again when reintroduced. Pain and decreased narcotic use sustained over a year RecoveryRx® – reduces chronic pain and narcotic medication use BASELINE 23 www.EchelonHealthPro.com
  23. 23. Patient undergoing painful Nephrostomy (Kidney drainage). Addition of RecoveryRx® reduced the pain being experienced by 75% (VAS 8 – 2). After starting RecoveryRx® patient asked for continuation of the therapy. Application of RecoveryRx®: Improves patient comfort RecoveryRx® VAS 8 VAS 2 VAS 2 24 www.EchelonHealthPro.com
  24. 24. RecoveryRx® Applications Back Wrap •Chronic & acute back pain •Disc issues •Radiculopathy •Muscle soreness •Back strains & sprains •Nighttime back pain •Sciatic nerve pain •Back surgery recovery Knee Wrap •Runners & jumpers knee •Tendonitis •Osteoarthritis •Knee strains & sprains •Ligament injury recovery •Knee surgery recovery Other Applications •Muscle & joint soreness •Neck & shoulder pain •Diabetic ulcers •Carpal tunnel •Tennis elbow •Sprained ankle •Neuropathy •Post surgical wounds Muscle & JointBack Pain Knee Pain 31 www.EchelonHealthPro.com
  25. 25. 5x Better Back Pain Relief Compared to OTC Drugs & 100% Safer RecoveryRx® Compared to Other Therapies 32 www.EchelonHealthPro.com
  26. 26. Pectoral Muscle Injury Rawe IM, Lowenstein A, Barcelo CR, Genecov DG: Control of postoperative pain with a wearable continuously operating pulsed radiofrequency energy device: a preliminary study. Aesthetic Plast Surg 36(2), 458-463 (2012). Postoperative Pain study: • Mainly a pectoral muscle injury due to implant placement. • Pain scores for 7 days recorded. • Pain significantly less in the study group on each day (p < 0.05) than control group (placebo). • 7 days shows the accumulated pain scores were 50% less in the study group. • The study group consumed significantly less narcotic pain medications during the recovery period (p = 0.002). 33 www.EchelonHealthPro.com
  27. 27. Delayed Onset Muscle Soreness RecoveryRx® Significantly Lowered DOMS Pain Score RecoveryRx® RecoveryRx® vs Acetaminophen p = 0.05 RecoveryRx® vs Control p = 0.001 34 DOMS in Bicep Muscle • Bicep muscle exercise to induce soreness 90 subjects • Randomized into three groups, control, acetaminophen, RecoveryRx®. • Muscle soreness assessed at 48 hours. DOMS study in Marathon Runners •Independent RCT - Aalborg University Hospital, Denmark. •Similar findings, significant decreased muscle soreness in study group as well increased post marathon exercise (running). www.EchelonHealthPro.com
  28. 28. Plantar Fasciitis - Clinical Study Plantar Fasciitis • Randomized control trial (RCT). • Average time with heel pain 13 months. • AM pain declined by 40% in the study group after 7 days of overnight therapy, • 7% in control group. • Decrease was statistically significant. • Trend to decreased medication use. New Clinical Trial Completed (University of BC): A six month follow up results show Smart Insole™ Therapy is superior for pain and disability improvements for recalcitrant PR than platelet rich plasma, steroid injection, dextrose and extracorporeal therapy. 36 www.EchelonHealthPro.com
  29. 29. Total mean SD median P value Placebo 145 18.1 5.9 20 - Active 77 8.5 4.6 7 0.002 Patients in the study used narcotic pain medications hydrocodone and oxycodone. The average daily pill use is shown for the 7 day study period. The active group used a significantly lower total (p = 0.002) amount of narcotic pain medication. Narcotic Pain Medication Use 37 www.EchelonHealthPro.com
  30. 30. • 72.5% reported a reduction in pain medication. • 61.3% reporting a moderately or greater reduction. • 16.5% completely eliminated pain medications Figure 4: Reduction in pain medication use Narcotic Pain Medication Use Patient Survey Results with RecoveryRx DECREASING MEDICATION USE Medication use 1. no effect, 2.reduced a little, 3. moderate amount, 4. large amount, 5. eliminated. 38 www.EchelonHealthPro.com
  31. 31. Articles Published Study Journal Publication Date Estimate Author Institution Blepharoplasty Aesthetic Plastic Surgery 1982;6(3):169-71 Frederick V. Nicolle, Richard M. Bentall London, United Kingdom Postoperative Pain Aesthetics of Plastic Surgery Published: 2012 Apr;36(2):458-63 Rawe IM, Lowenstein A.Barcelo CR, Genecov DG Genecov Plastic Surgery Group Dallas, Texas Chronic Wound Case Study International Wound Journal Published: 2012 Jun;9 (3):253-8 T. Vlahovic, IM Rawe Temple University Philadelphia, PA Plantar Fasciitis Journal of Foot and Ankle Surgery Published: 2012 May – June;51(3):312-6 Brook J, Dauphinee DM Korpinen J, Rawe IM Hunts Regional Medical Center Greenville, Texas Osteoprogeniter Cell Differentiation In To Bone Journal of Craniofacial Surgery Published 2012 Mar;23(2):586-93 Dr. Russell Reid University of Chicago Medical School DOMS Marathon Runners PLOS Medicine April 2014 Dr. Sten Rasmussen AARHUS University Hospital Aalborg, Denmark Case for OTC use of shortwave therapy Pain Management January 2014 Ian Rawe BioElectronics Updated 10-4-13 40 www.EchelonHealthPro.com
  32. 32. Current Clinical Trials Study Principal Investigator Location Primary Outcome Measure Enrollment Status Plantar Fasciitis Professor Jack Taunton University British Columbia, Vancouver, Canada Pain at 4 weeks, follow up at 6 months 40 (60) Complete – data analysis Osteoarthritis knee pain Professor Gianluca Bagnato University Hospital G. Martin, Messina, Italy Knee pain and edema at 4 weeks 60 Completion Date November 2013 Lower Back Pain Dr. Steve Tumilty University of Dunedin, Otago, New Zealand Lower back pain 40 Completion Date November 2013 Bilateral Hernia Surgical Recovery Dr. Frederik Berreveot University Hospital Ghent, Ghent, Belgium Analgesic medication use and pain over 7 day recovery. 50 Completion Date April 2014 Venous ulcer wound healing Dr. Sten Rasmussen AARHUS University Hospital Aalborg, Denmark Wound healing and pain 40 Recruitment complete 3rd Molar Extraction Dr. William Gilmore Tuft Dental School, Boston, MA Pain and Edema at day 1, 3 and 5 60 Recruiting Craniofacial pain case studies Dr. Steven Scrivani Tuft Dental School, Boston, MA Myofascial pain - Proceeding with ethics approval Chronic Wound Pain Geert VanWellegham CNS Wondzorg, decubitus-en valpreventie H-Hartziekenhuis Roeselare-Menen vzw Chronic wound pain case studies - Ongoing Menstrual Pain Dr. Justin Clark Consultant Obstetrician and Gynecologist Birmingham Woman’s Hospital, UK Menstrual pain MOOS 200 Protocol Development/ethics approval Updated 10-4-13 41 www.EchelonHealthPro.com
  33. 33. 1) Is RecoveryRx® safe? Yes. Shortwave therapies have a long history of safe use. RecoveryRx® is a non-invasive, localized therapy which can be worn by diabetics, arthritics, the elderly and bedridden. Over 500,000 products have sold worldwide with no adverse effects. 2) Is RecoveryRx® safe to use with metal implants and pacemakers? The RF field strength is too low for any significant heating from implanted metal so it is safe for all metal implants. There is no concern for pacemakers as they have built in RF protection. Though as a precaution, we don’t recommend using directly over the pacemaker. 3) Is RecoveryRx® a magnet? No. RecoveryRx® is not a magnet. It is a battery operated, pulsed shortwave electromagnetic field medical device. When activated, RecoveryRx® uses a pulsed shortwave radiofrequency to deliver a low level of energy into the injured tissue reducing pain, inflammation and promoting healing. 4) What will my patients feel when using the device? Only better. They will not feel the low level energy that is gently pulsed into the cells to restore damaged tissue. The device is sensation and odor free. Frequently Asked Questions 42 www.EchelonHealthPro.com
  34. 34. 5) How long until the patient will begin to feel relief? Pain is a very subjective sensation; however, patient pain levels will begin to subside typically after only 2-3 hours of wearing the device and will continue to lessen as long as the device is being used continuously. 6) Can the patient wear more than one device? Yes. You can wear more than one RecoveryRx® medical device at a time just as long as more than one device is not directly on top of another. 7) Does RecoveryRx® need to be in direct contact with the skin? No. While RecoveryRx® can be used in direct contact with the skin, the device’s energy is able to pass through wound dressing, various wraps and light clothing for easy application. 8) Can RecoveryRx® be placed under compression dressings? No. RecoveryRx® can’t be used under compression dressings; however, the device can be used over the compression dressing with the energy passing through to the tissue below. Frequently Asked Questions 43 www.EchelonHealthPro.com
  35. 35. 44

×